Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines

Biomedical Research

Volumn 29, Issue 6, 2008, Pages 271-278

  Tochizawa, Shiro ^a   Masumori, Naoya ^b   Yanai, Yoshiaki ^a   Ohmoto, Yasukazu ^a   Yabuuchi, Youichi ^a   Tsukamoto, Taiji ^b  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE; SORAFENIB; VASCULOTROPIN; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PYRIDINE DERIVATIVE; VASCULOTROPIN A;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MITOSIS INHIBITION; MONOTHERAPY; PROTEIN SYNTHESIS INHIBITION; CELL PROLIFERATION; DRUG EFFECT; KIDNEY TUMOR; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PYRIDINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 59649129050     PISSN: 03886107     EISSN: 1880313X     Source Type: Journal    
DOI: 10.2220/biomedres.29.271     Document Type: Article

References (29)

1. Arora T, Floyd-Smith G, Espy MJ and Jelinek DF (1999) Dissociation between IFN-α-induced anti-viral and growth signaling pathways. J Immunol 162, 3289-3297.
2. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, Wilkie D, Carter CA, Taylor IC, Lynch M and Wilhelm S (2007) Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59, 561-574.
3. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R and Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356, 125-134.
4. Gollob JA (2005) Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. Clin Genitourin Cancer 4, 167-174.
5. Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G, Watkins C, Gu L, Peterson BL and Wright JJ (2007) Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 25, 3288-3295.
6. Inamura K, Matsuzaki Y, Uematsu N, Honda A, Tanaka N and Uchida K (2005) Rapid inhibition of MAPK signaling and anti-proliferation effect via JAK/ STAT signaling by interferon-α in hepatocellular carcinoma cell lines. Biochim Biophys Acta 1745, 401-410.
7. Jacobsen J, Rasmuson T, Grankvist K and Ljungberg B (2000) Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 163, 343-347.
8. Jung YD, Nakano K, Liu W, Gallick GE and Ellis LM (1999) Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells. Cancer Res 59, 4804-4807.
9. Lamberti A, Longo O, Marra M, Tagliaferri P, Bismuto E, Fiengo A, Viscomi C, Budillon A, Rapp UR, Wang E, Venuta S, Abbruzzese A, Arcari P and Caraglia M (2007) C-Raf antagonizes apoptosis induced by IFN-α in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A. Cell Death Differ 14, 952-962.
10. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M and Carter C (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in Hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66, 11851-11858.
11. Milanini J, Viñals F, Pouysségur J and Pagès G (1998) p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J Biol Chem 17, 18165-18172.
12. Miyao N, Tsukamoto T and Kumamoto Y (1989) Establishment of three human renal cell carcinoma cell lines (SMKT-R-1, SMKT-R-2, and SMKT-R-3) and their characters. Urol Res 17, 317-324.
13. Murphy DA, Makonnen S, Lassoued W, Feldman MD, Carter C and Lee WM (2006) Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol 169, 1875-1885.
14. Nathan P, Chao D, Brock C, Savage P, Harries M, Gore M. and Eisen T (2006) The place of VEGF inhibition in the current management of renal cell carcinoma. Br J Cancer 94, 1217-1220.
15. Nicol D, Hii SI, Walsh M, Teh B, Thompson L, Kennett C and Gotley D (1997) Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol 157, 1482-1486.
16. Okajima E and Thorgeirsson UP (2000) Different regulation of vascular endothelial growth factor expression by the ERK and p38 kinase pathways in v-ras, v-raf, and v-myc transformed cells. Biochem Biophys Res Commun 270, 108-111.
17. Romerio F, Riva A and Zella D (2000) Interferon-α2b reduces phosphorylation and activity of MEK and ERK through a Ras/ Raf-independent mechanism. Br J Cancer 83, 532-538.
18. Romerio F and Zella D (2002) MEK and ERK inhibitors enhance the antiproliferative effect of interferon-α2b. FASEB J 16, 1680-1682.
19. Ryan CW, Goldman BH, Lara PN Jr, Mack PC, Beer TM, Tangen CM, Lemmon D, Pan CX, Drabkin HA and Crawford ED (2007) Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 25, 3296-3301.
20. Schips L, Dalpiaz O, Lipsky K, Langner C, Rehak P, Puerstner P, Pummer K and Zigeuner R (2007) Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Fur Urol 51, 168-174.
21. Shang D, Liu Y, Ito N, Kamoto T and Ogawa O (2007) Defective Jak-Stat activation in renal cell carcinoma is associated with interferon-α resistance. Cancer Sci 98, 1259-1264.
22. Stancato LF, Sakatsume M, David M, Dent P, Dong F, Petricoin EF, Krolewski JJ, Silvennoinen O, Saharinen P, Pierce J, Marshall CJ, Sturgill T, Finbloom DS and Larner AC (1997) Beta interferon and oncostatin M activate Raf-1 and mitogen-activated protein kinase through a JAK1-dependent pathway. Mol Cell Biol 17, 3833-3840.
23. Takahashi A, Sasaki H, Kim SJ, Tobisu K, Kakizoe T, Tsukamoto T, Kumamoto Y, Sugimura T and Terada M (1994) Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 54, 4233-4237.
24. Von Marschall Z, Scholz A, Cramer T, Schäfer G, Schirner M, Oberg K, Wiedenmann B, Höcker M and Rosewicz S (2003) Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 95, 437-448.
25. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D and Marais R (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867.
26. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G and Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64, 7099-7109.
27. Yanagawa H, Takeuchi E, Suzuki Y, Ohmoto Y, Bando H and Sone S (1999) Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol Immunother 48, 396-400.
28. Yanai Y, Sanou O, Kayano T, Ariyasu H, Yamamoto K, Yamauchi H, Ikegami H and Kurimoto M (2001) Analysis of the antiviral activities of natural IFN-α preparations and their subtype compositions. J Interferon Cytokine Res 21, 835-841.
29. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E and Lokshin AE (2007) Multiplex analysis of serum cytokines in melanoma patients treated with interferon-α2b. Clin Cancer Res 13, 2422-2428.